Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2226 • ACR Convergence 2022
Accelerated Aging Based on Blood DNA Methylation in SLE Participants Compared to Healthy Controls
Joanne Nitithalm¹, Olivia Solomon², Laura Trupin³, Patricia Katz⁴, Jinoos Yazdany⁴, Maria Dall'Era⁵, Lisa F Barcellos², Lindsey Criswell⁶ and Cristina M Lanata⁷, ¹NIH/NHGRI, Bethesda, MD, ²University of California, Berkeley, Berkeley, CA, ³UC San Francisco, San Francisco, CA, ⁴UCSF, San Rafael, CA, ⁵University of California, Division of Rheumatology, San Francisco, CA, ⁶National Human Genome Research Institute, NIH, Bethesda, MD, ⁷NIH/NHGRI, Washington, DC
Background/Purpose: Epigenetic clocks based on DNA methylation in blood have been shown to correlate with biological aging and predict adverse health outcomes, including mortality. Accelerated…
Abstract Number: 0064 • ACR Convergence 2022
Utilization of Preventive Services in a Systemic Lupus Erythematosus Population-Based Cohort: A Lupus Midwest Network Study
Baptiste Chevet¹, Gabriel Figueroa Parra¹, Jeffrey X. Yang¹, Mehmet Hocaoglu¹, Shirley-Ann Osei-Onomah¹, Cassondra Hulshizer¹, Tina Gunderson¹, Divi CORNEC², Cynthia Crowson³ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²CHRU Brest, Brest, France, ³Mayo Clinic, Eyota, MN
Background/Purpose: Systemic lupus erythematosus (SLE) is a disease that can damage multiple organs and, along with certain treatments, increase the risk of developing cancer, cardiovascular…
Abstract Number: 0183 • ACR Convergence 2022
LupusConnect™: A 24/7 Online Lupus Support Community
Leticia Ocana, Ashley Holden and Daria McClamb, Lupus Foundation of America, Washington, DC
Background/Purpose: A Lupus Foundation of America (LFA) National Needs Assessment Survey in 2015 with 3402 lupus patients and caregivers found that the number one need…
Abstract Number: 0331 • ACR Convergence 2022
Anti-dsDNA Antibodies by Multiplex Flow Immunoassay and Critihidia Luciliae Assays in NYU Lupus Registry: Discordance, Association with Nephritis, and Disease Flare Predictive Value
Devyn Zaminski¹, Amit Saxena¹, Peter Izmirly², Jill Buyon² and H Michael Belmont¹, ¹NYU School of Medicine, New York, NY, ²NYU Grossman School of Medicine, New York, NY
Background/Purpose: SLE is characterized by autoantibody production. The most common lupus-specific serology is the anti-dsDNA antibody (anti-DNA). Traditionally, anti-DNA is measured by an enzyme immunoassay…
Abstract Number: 0348 • ACR Convergence 2022
Significant Improvement in Cutaneous Lupus Erythematosus with or Without Systemic Lupus Erythematosus with Belimumab Use – a Systematic Review and Meta-Analysis
Rachel Kneeland¹, Daniel Montes¹, Justin endo¹, Bridget Shields¹, Christie Bartels² and Shivani Garg³, ¹University of Wisconsin, School of Medicine and Public Health, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI, ³University of Madison, School of Medicine and Public Health, Madison, WI
Background/Purpose: Cutaneous lupus erythematosus (CLE) with or without systemic lupus erythematosus (SLE), can be debilitating and cause significant scarring and psychological distress. Belimumab, a monoclonal…
Abstract Number: 0370 • ACR Convergence 2022
Preliminary Findings from a Randomized Clinical Trial Show a Remotely Delivered Psychological Intervention May Be Beneficial to Youth with Childhood-Onset Lupus
Natoshia Cunningham¹, Samantha Ely¹, ashley Danguecan², Mallet Reid³, Alaina Miller⁴, Mathew Reeves³, Lawrence Ng², Paris Moaf², Sarah Mossad², Tala El Tal⁵, Luana Flores Pereira², Deborah Levy⁶, Linda Hiraki⁷, Jennifer Stinson², Sara Ahola Kohut², khalid abulaban⁸, Elizabeth Kessler⁹, Stacy Allen⁸, Tamar Rubinstein¹⁰, Evin Rothschild¹¹, Natalie Rosenwasser¹², Kabita Nanda¹², Susan Canny¹², Emily Smitherman¹³, Livie Huie¹³, James Birmingham¹⁴, Allison Thompson¹⁵, Janel Thompson¹⁵, Miranda Moyer¹⁵, Angela Chapson Emily Nguyen¹⁵ and Andrea Knight⁵, ¹Michigan State University, Grand Rapids, MI, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Michigan State University, East Lansing, MI, ⁴Wright State University, Dayton, OH, ⁵The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁶Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁷The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Genetics and Genome Biology, SickKids Research Institute, Toronto, ON, Canada, ⁸Spectrum Health, Grand Rapids, MI, ⁹Spectrum Health Helen DeVos Children's Hospital, Michigan State University, Grand Rapids, MI, ¹⁰Albert Einstein College of Medicine, White Plains, NY, ¹¹Children's Hospital at Montefiore, Bronx, NY, ¹²Seattle Children's Hospital, Seattle, WA, ¹³University of Alabama at Birmingham, Birmingham, AL, ¹⁴Metro Health, Grand Rapids, MI, ¹⁵Patient/Caregiver Co-Investigative Team, Grand Rapids, MI
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is often associated with symptoms such as fatigue, pain, and depressive symptoms that contribute to poor health-related quality of…
Abstract Number: 0635 • ACR Convergence 2022
Blood RNA-sequencing Reveals Complex Immune Dysregulation in ANA-positive Individuals with Distinct Profiles Preceding Progression to SLE versus Stable Autoimmunity
Lucy Marie Carter¹, Md Yuzaiful Md Yusof², Darren Plant³, Julien Bauer⁴, Stephanie Wenlock⁴, Adewonuola Alase¹, Antonios Psarras¹, Zoe Wigston¹ and Edward M Vital², ¹University of Leeds, Leeds, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³The University of Manchester, Manchester, United Kingdom, ⁴University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Anti-nuclear antibody (ANA) positivity represents a complex ‘At-Risk’ state for development of connective tissue disease (CTD). ANA may become positive years in advance of…
Abstract Number: 0655 • ACR Convergence 2022
Proteomic Analysis of Histological Lesions Lupus Nephritis Identifies an Inflammatory Signature of Fibrous Crescents
Alessandra Ida Celia¹, Jeffery Hodgin², Avi Rosenberg³, Laurence S Magder⁴, Jill Buyon⁵, Betty Diamond⁶, Judith James⁷, William Apruzzese⁸, Paride Fenaroli⁹, Derek Fine¹, Jose Monroy-Trujillo¹, Mohamed G. Atta¹, Peter izmirly¹⁰, Michael Belmont⁵, Anne Davidson⁶, Daniel W. Goldman¹¹, the Accelerating Medicines Partnership (AMP) RA/SLE¹², Michelle Petri¹¹ and Andrea Fava¹, ¹Johns Hopkins University, Baltimore, MD, ²University of Michigan, Ann Arbor, MI, ³Johns Hopkins University, Ballwin, MO, ⁴University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD, ⁵NYU Grossman School of Medicine, New York, NY, ⁶Feinstein Institutes for Medical Research, Manhasset, NY, ⁷Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Brigham and Women's Hospital, Boston, MA, ⁹Università degli Studi di Parma, Parma, Emilia-Romagna, Italy, ¹⁰NYU Long Island School of Medicine, New York, NY, ¹¹Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ¹²Multiple Insitutions
Background/Purpose: We employed urine proteomics to define the molecular signatures associated with the histological features quantified by the NIH activity and chronicity indices. Methods: Glomerular…
Abstract Number: 0715 • ACR Convergence 2022
Safety and Immunogenicity of Mixed COVID19 Vaccine Regimens in Immune-mediated Inflammatory Diseases: An Observational Cohort
Carol Hitchon¹, Christine Mesa², Charles N Bernstein¹, Catherine Card², RuthAnn Marrie¹, Sheila O'Brien³ and John Kim², ¹University of Manitoba, Winnipeg, MB, Canada, ²Public Health Agency of Canada, Winnipeg, MB, Canada, ³Canada Blood Services, Ottawa, Canada
Background/Purpose: Data on immunogenicity and safety of COVID-19 vaccination strategies exist for the general population, however, such data are limited for immunocompromised people including those…
Abstract Number: 0959 • ACR Convergence 2022
Assessing the Association Between Hydroxychloroquine and Preeclampsia Risk in SLE Pregnancies Using Administrative Claims Data
Amadeia Rector¹, Ivana Marić², Yashaar Chaichian³, Eliza Chakravarty⁴, Miranda Cantu⁵, Michael Weisman⁶, Gary Shaw⁷, Maurice Druzin⁷ and Julia Simard¹, ¹Stanford University School of Medicine, Palo Alto, CA, ²Stanford University, Stanford, ³Stanford University, Stanford, CA, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Global Lupus Support Group, Portage, MI, ⁶Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁷Stanford University School of Medicine, Palo Alto
Background/Purpose: Preeclampsia risk is higher among pregnancies in patients with systemic lupus erythematosus (SLE). Hydroxychloroquine (HCQ), a common first-line treatment, is encouraged in SLE pregnancies…
Abstract Number: 0980 • ACR Convergence 2022
The Effect and Outcomes of HCQ Alone and in Combination with Anti-Depressants on QTc
Kourtney Rudzinski¹, Zaina Shahid², Yasin kanakrieh², Saloni Goyal², Kyle Shaak² and James Ross³, ¹Lehigh Valley Health Network, Tatamy, PA, ²Lehigh Valley Health Network, Allentown, PA, ³lvhn, Macungie, PA
Background/Purpose: Hydroxychloroquine (HCQ) has faced increased scrutiny during the COVID pandemic for its association with QTc prolongation. In our field, patients are commonly on antidepressant…
Abstract Number: 0997 • ACR Convergence 2022
Withdrawal of Maintenance Glucocorticoid versus Other Immunosuppressants Among Patients with Systemic Lupus Erythematosus in Long Term Clinical Remission: Interim Analysis of a Non-inferiority Randomised Controlled Trial
Aishwarya Gopal¹, Chengappa Kavadichanda², Devender Bairwa³, Molly Mary Thabah⁴ and Vir Singh Negi⁵, ¹Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, Puducherry, India, ²JIPMER, Pondicherry, Puducherry, India, ³Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, Puducherry, India, ⁴JIPMER, Puducherry, Puducherry, India, ⁵AIIMS Bilaspur, Puducherry, Puducherry, India
Background/Purpose: Attempts to stop glucocorticoids among Systemic Lupus Erythematosus(SLE) patients in long term remission have been successful. Continuing other immunosuppressive (IS) agents indefinitely is currently…
Abstract Number: 1141 • ACR Convergence 2022
Consequences of SLE Heterogeneity on the Epigenome and the Drivers Behind
Olivia Castellini-Pérez¹, Athina Spiliopoulou², Guillermo Barturen¹, Andrii Iakovliev², Manuel Martinez-Bueno¹, Elena Carnero-Montoro¹ and Marta Alarcon-Riquelme¹, ¹Center for Genomics and Oncological Research (GENYO), Granada, Spain, ²University of Edinburgh, Edinburgh, Scotland, United Kingdom
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a prototypic systemic autoimmune disease characterized by a complex aetiology and heterogenous symptomatology which has been recently dissected using…
Abstract Number: 1352 • ACR Convergence 2022
Improving Completion Rates of Routine Mental Health Screening for Depression and Anxiety in Paediatric Lupus Outpatient Clinic to Enhance Patient Mental Health Care
Tala El Tal¹, Avery Longmore², Abdulaziz el Mutairi¹, Amani Al Bijadi¹, Audrea Chen¹, Holly Convery¹, Dinah Finkelstein³, Linda Hiraki⁴, Chetana Kulkarni⁵, Justine Ledochowski⁶, Neely Lerman¹, Karen Leslie⁷, Deborah Levy⁸, Sharon Lorber⁹, Jayne MacMahon¹⁰, Jeanine McColl¹¹, Sarah Mossad¹², Oscar Mwizerwa¹⁰, Lawrence Ng¹², Luana Flores Pereira¹², Vandana Rawal⁷, Alaa Shehab¹, Evelyn Smith¹³, Alene Toulany¹⁴ and Andrea Knight¹, ¹The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ²The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ³The Hospital for Sick Children, Department of Paediatrics, University of Toronto, ON, Canada, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Genetics and Genome Biology, SickKids Research Institute, Toronto, ON, Canada, ⁵The Hospital for Sick Children, Division of Child & Youth Mental Health, Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ⁶The Hospital for Sick Children, Department of Psychology, University of Toronto, Toronto, ON, Canada, ⁷The Hospital for Sick Children, Division of Adolescent Medicine, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁹The Hospital for Sick Children, Factor Inwentash Faculty of Social Work, University of Toronto, Toronto, ON, Canada, ¹⁰The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, Toronto, ON, Canada, ¹¹University of Toronto, Toronto, ON, Canada, ¹²The Hospital for Sick Children, Toronto, ON, Canada, ¹³The Hospital for Sick Children, Division of Psychiatry, Department of Paediatrics, University of Toronto,, Toronto, ON, Canada, ¹⁴The Hospital for Sick Children, Division of Adolescent Medicine, Department of Paediatrics, University of Toronto,, Toronto, ON, Canada
Background/Purpose: Mental health (MH) problems are prevalent in adolescents with childhood-onset lupus (cSLE), with cross-sectional studies estimating prevalences of 20-60% for depression symptoms and 20-40%…
Abstract Number: 1442 • ACR Convergence 2022
Role of Platelet-bound Complement Activation Product (PC4d) in Predicting Risk of Future Thrombotic Events in Systemic Lupus Erythematosus
Anca Askanase¹, John Conklin², Michelle Petri³, Vasileios Kyttaris⁴, Yevgeniya Gartshteyn⁵, Wei Tang¹, Anja Kammesheidt⁶ and Roberta Alexander², ¹Columbia University Medical Center, New York, NY, ²Exagen, Inc., Vista, CA, ³Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁴Beth Israel Deaconess Medical Center, Boston, MA, ⁵Columbia University Medical Center, Glen Rock, NJ, ⁶self, Laguna Beach, CA
Background/Purpose: Platelet-bound complement activation products (PC4d) are associated with a history of thrombosis in systemic lupus erythematosus (SLE) (Gartshteyn al., 2021; Petri et al., 2017).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].